Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients With Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103

NCT04246866 is registered in ClinicalTrials.gov with Gemini Therapeutics, Inc. as lead sponsor.

NCT NCT04246866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04246866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients With Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103
Lead sponsor
Gemini Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 19, 2019
Completion date
October 21, 2020
Enrollment
12 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration, geographic atrophy, macular degeneration, retinal degeneration, retinal disease